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Summary Constant denaturant gel electrophoresis (CDGE) was used to screen 179 breast carcinomas for
mutations in the conserved regions of the TP53 gene (exons 5 through 8). Mutations were found in 35 of 163
primary tumours (21%) and in 5 of 16 metastases (31%) and resided predominantly in exon 7. The majority
of the mutations were G:C+A:T transitions. Immunohistochemistry demonstrated nuclear accumulation of
p53 protein in 35 of 162 primary tumours (22%) and in four of 15 metastases (27%). TP53 mutation was
strongly associated with nuclear accumulation of p53 protein. In total 42 of 163 primary tumours (26%) and 5
of 16 metastases (31%) were demonstrated to contain TP53 alterations (mutation and/or nuclear protein
accumulation). TP53 alteration in primary tumour was significantly associated with the following parameters:
positive node status, T status > 1, negative oestrogen receptor status, negative progesterone receptor status,
presence of ERBB2 gene amplification, and invasive ductal histology. Furthermore, there were statistically
significant associations, independent of other prognostic factors, between TP53 alterations in primary tumour
and disease-free and overall survival.
Mutations in the TP53 gene have been found in a variety of
human malignancies, and are considered to represent the
most common genetic alterations in human cancer (Levine et
al., 1991). Inherited mutations in the heterozygous state have
been described in noncancerous cells from members of Li-
Fraumeni syndrome families (Malkin et al., 1990; Srivastava
et al., 1990), and have recently been identified in breast
cancer patients outside such families as well (B0rresen et al.,
1992; Malkin et al., 1992; Prosser et al., 1992; Sideransky et
al., 1992).
The TP53 tumour suppressor gene is located at chromo-
some 17pl3.1 and encodes a 53 kDa cell cycle regulatory
nuclear phosphoprotein (Levine et al., 1991; Lane, 1992).
Most of the TP53 mutations reported in human cancers are
located within the evolutionary conserved regions of the gene
(codons 110-307 of totally 393) (Hollstein et al., 1991;
deFromentel & Soussi, 1992). The mutations usually are
missense, giving rise to altered proteins (Levine et al., 1991).
An altered conformation enables most of the mutant proteins
to inactivate wild-type protein by forming inactive oligomeric
complexes (Nigro et al., 1989). Most of the mutant p53
proteins have considerable longer half-life than wild-type
protein, resulting in accumulation of the mutant protein in
the transfected or neoplastic cells (Hinds et al., 1990; Iggo et
al., 1990).
The negative r:egulatory effects of TP53 upon cell prolifera-
tion has been demonstrated to be inactivated by mutations
and by the presence of DNA virus proteins (Lane, 1992;
Vogelstein & Kinzler, 1992). Furthermore, increased levels of
MDM2 protein and sequestering of p53 protein in the cyto-
plasm have been suggested to be associated with inactivation
of TP53 tumour suppressor function (Moll et al., 1992;
Momand et al., 1992; Oliner et al., 1992; Vogelstein & Kinz-
ler, 1992).
Several findings indicate that inactivation of TP53 is
associated with a growth advantage in breast carcinoma:
Accumulation of p53 protein has been reported to be
associated with high grade tumours, increased levels of
epidermal growth factor receptor (EGFR), presence of the
proliferation associated antigen Ki67, advanced stage, metas-
tatic spread, and low concentrations of oestrogen and pro-
gesterone receptors (Cattoretti et al., 1988; Thompson et al.,
1990; Davidoff et al., 1991a; Varley et al., 1991; Mazars et
al., 1992). Recent reports conclude that positive p53
immunostaining in primary tumour represents a prognostic
parameter, suggesting that p53 protein accumulation might
become clinically useful as an indicator of breast cancer
aggressiveness (Iwaya et al., 1991; Ostrowsky et al., 1991;
Varley et al., 1991; Isola et al., 1992; Mazars et al., 1992;
Thor et al., 1992).
The aims of the present study were (a) to determine the
nature and frequency of both TP53 mutations and p53 pro-
tein accumulation in breast carcinomas, (b) to study the
associations between TP53 alterations, ERBB2 gene amplifi-
cation, histopathological and clinical parameters, and (c) to
evaluate if TP53 alterations provide prognostic information
in primary breast carcinoma.
Materials and methods
Patient material
Material for this study was obtained from 163 patients with
primary breast carcinomas and 16 patients with breast car-
cinoma metastases admitted to The Norwegian Radium Hos-
pital during the period from 1984 to 1989. The 163 patients
with primary carcinoma that were included in the survival
studies had a mean observation time of 45.8 months (range
0.1 to 94.1 months, median 38.3 months) and a mean age at
diagnosis of 56.6 years (range 31.1 to 85.6 years, median 56.5
years). Lymph node dissection was performed on all but four
of the patients with primary carcinoma. Tumour and node
status was decided based on the pathologists reports, accord-
ing to the 1988 TNM classification (Beahrs et al., 1988).
Formalin-fixed, paraffin embedded tumour tissue from each
case was processed for light microscopy and examined by the
pathologist (JMN) according to the WHO criteria.
Tumour tissue was obtained from each patient at surgery.
The samples included 163 primary tumours, 12 locoregional
recurrences, two supraclavicular, one bronchial, and one skin
metastasis. The tumour tissue was immediately frozen and
stored in liquid nitrogen for DNA and hormone receptor
analyses. Frozen tissue for immunohistochemistry was
available from 51 of the primary tumours and nine of the
metastases, whereas paraffin embedded tumour tissue for
such analyses was available in all but two (one primary
tumour and one metastasis) of the remaining cases.
DNA analyses
DNA was isolated from tumour tissue by phenol/chloro-
phorm extraction followed by ethanol precipitation (Kunkel
et al., 1977). Amplification of exons 5-8 of the TP53 gene
was performed by the polymerase chain reaction (PCR) using
primers and conditions as previously described (B0rresen et
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al., 1991; Smith-S0rensen et al., in press). The five PCR
fragments covered the evolutionary conserved regions of the
gene, in which more than 80% of the reported mutations
have been found; codons 128-153 (exon 5), codons 155-185
(exon 5), codons 189-215 (exon 6), codons 237-253 (exon
7), and codons 265-301 (exon 8). The five fragments from
each tumour were screened for TP53 mutations using con-
stant denaturant gel electrophoresis (CDGE) as previously
described (B0rresen et al., 1991; Condie et al., in press;
Smith-S0rensen et al., in press). Samples that had abberantly
migrating bands in the CDGE analyses were reamplified and
the abberant bands were confirmed by perpendicular
denaturing gradient gel electrophoresis (DGGE). Exon 6
fragments that gave abberant bands were digested with TaqI
and analysed on a polyacrylamide gel to identify samples
with the codon 213 A-*G polymorphism (Serra et al., 1992).
All PCR fragments that had a mobility different from normal
DNA in CDGE and DGGE analyses were considered to be
mutant, except the exon 6 fragments demonstrated to contain
the codon 213 polymorphism. Mutant samples were sub-
mitted to PCR with one biotinylated primer, and were
sequenced directly with standard dideoxy sequencing reac-
tions, using Dynabeads M280-Streptavidin (Dynal AS, Nor-
way) as solid support.
Mutation analysis (exons 5, 7 and 8) of 32 of the samples
and ERBB2 gene amplification studies of 121 of the primary
tumours have previously been published (B0rresen et al.,
1990; B0rresen et al., 1991; Ottestad et al., in press).
Immunohistochemistry
Frozen sections and paraffin embedded tissue were immuno-
stained using the avidin-biotin-peroxidase complex (ABC)
method (Hsu et al., 1981). The frozen sections were air-dried
overnight, fixed in cold acetone at 4°C for 10 min and
washed in phosphate buffered saline (PBS), pH 7.4. The
paraffin embedded tissue was fixed in 4% buffered formalde-
hyde at room temperature. Four to six gm thick sections
from paraffin embedded blocks were mounted on coated
slides and incubated for 30 min at 56°C and overnight at
37°C. The three monoclonal antibodies PAb 421, PAb 1801,
and PAb 240 (Oncogene Science) were applied on frozen
sections, whereas PAb 1801 and the polyclonal NCL-CM1
(Novacastra Laboratory Ltd.) were applied on paraffin
embedded material. Twenty-two tumours were tested with
PAb 1801 on frozen sections as well as paraffin embedded
tissue to compare the quality of the stainings. PAb 421, PAb
1801, and NCL-CM1 detect mutant and wild-type protein,
whereas PAb 240 recognises mutant and denatured wild-type
protein. Briefly, the sections were incubated for 18-22 h at
4°C with specific primary antibodies (PAb 421 diluted 1:100
(1 figIgG2U mI'), PAb 1801 diluted 1:300 (0.33 gtg IgG,
ml-), PAb 240 diluted 1:100 (1 jg IgG, ml-'), and NCL-
CM1 diluted 1:300). The reactions were then incubated with
biotin labelled secondary antibody and avidin-biotin-
peroxidase complex. The peroxidase reaction was developed
using diamino-benzidine as a chromogen. All series included
positive controls. Negative controls included substitution of
polyclonal primary antiserum with rabbit serum diluted
1:300, whereas negative controls for the monoclonal
antibodies were performed using mouse myeloma protein of
the same subclass and concentration as the monoclonal
antibody. All controls gave satisfactory results. Only cells
with nuclear staining were scored as p53 protein immuno-
positive. The amount ofimmuno-positive cells was semiquan-
titatively estimated.
Oestrogen andprogesterone receptor determinations
Oestrogen and progesterone receptors were determined using
monoclonal antibodies in an enzyme immunoassay for quan-
titative measurement (Abbott ER and PgR-EIA monoclonal).
Samples with a receptor concentration exceeding 9 pmol g-'
protein were considered to be receptor positive.
Statistical analyses
Comparisons between groups were performed using Chi
square tests with Yates' correction. Disease free and overall
survival were calculated using the life-table method, and
differences between survival curves were tested using the log
rank test. To simultaneously analyse the importance of
several prognostic factors, the Cox proportional hazard
model (Cox, 1972) with a stepwise procedure, was used. The
following variables were included in the analyses: TP53
mutation, nuclear p53 protein accumulation, TP53 altera-
tions (mutation and/or nuclear protein accumulation), node
status (node negative vs node positive), T-status (T = 1 vs
T> 1), ERBB2 gene amplification, oestrogen and pro-
gesterone receptor status. ERBB2 gene amplification was not
included in the multivariate analyses since 42 of the primary
tumours were lacking ERBB2 data. P-values < 0.05 were
considered statistically significant. All statistical analyses
were performed using the BMDP statistical software package
(Dixon et al., 1990).
Table I TP53 mutations and nuclear p53 protein accumulation
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Figure 1 a, Constant denaturant gel electrophoresis (CDGE) of PCR amplified exon 7 fragments from tumour no. 132 (bronchial
metastasis) (lane 1), a known codon 248 mutant (CGGG+TGG) (lane 2), and wild-type tumours (lanes 3-5). The 12.5%
polyacrylamide gel contained 45% denaturant (100% denaturant corresponds to 7 M urea and 40% formamide) and was run for
2 h at 56°C at 80 V constant. b, PCR amplified exon 7 fragment of tumour no. 132 analysed on a 12.5% polyacrylamide gel with a
10-60% gradient of denaturant. The PCR product was loaded into a long well on the top of the gel and run with the
electrophoresis direction perpendicular to the denaturant gradient for 2 h at 56°C at 80 V constant. c, Sequencing analysis of PCR
amplified exon 7 of tumour no. 132. A CGGG+CAG substitution is seen in codon 248.
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Results
TP53 mutation analyses
The CDGE analyses demonstrated that 35 of the 163
primary tumours (22%) and 5 of the 16 metastases (31%)
contained mutations in exons 5 through 8. One primary
tumour contained two independent mutations (tumour no. 29,
Table I). A representative CDGE gel is shown in Figure la.
Samples that were suspected to harbour mutations were
reamplified and submitted to DGGE (Figure lb). PCR
fragments that had a mobility different from normal DNA in
the CDGE and DGGE were considered to be mutant. How-
ever, exon 6 fragments that had aberrant bands were not
considered to be mutant if they contained the polymorphic
TaqI site in codon 213.
The approximate position and nature of each mutation
could be predicted from these gels. For instance, fragments
that migrated more slowly than the wild-type were con-
sidered to have undergone G:C-*A:T transitions, since such
mutations result in the destabilizing loss of a hydrogen bond.
The exon in which each mutation resided, is given in Table I.
Thirteen mutations were found in exon 5, three in exon 6,
twelve in exon 7, and thirteen in exon 8. Accordingly, muta-
tions were most frequently observed in exon 7 (0.235
mutations/base pair screened in exon 7 vs 0.117, 0.076, and
0.037 mutations/base pair screened in exons 8, 5 and 6,
respectively, P = 0.0014).
Samples that were mutant according to the melting gel
analyses (CDGE and DGGE) were submitted to direct
sequencing (Figure lc and Table II). The sequence analyses
failed to confirm mutations in six samples that were mutant
according to the melting gels. These results were confirmed
by reamplification and resubmission to CDGE, DGGE, and
sequence analysis. It should be noted that the mutant bands
were faint in three of the six tumours (tumours no. 118, 228
and 416), but that the heteroduplexes convincingly indicated
mutations. Furthermore, four of the six samples had nuclear
accumulation of p53 protein (tumours no. 406, 416, 440, and
449, Tables I and II).
Table II shows that 29 point mutations and six deletions
were found by sequencing. Five point mutations were found
in codon 248, three in codon 273, and two in codons 128,
281, and 282. The majority of the point mutations appeared
at G:C base pairs (22 of 29, 76%). G:C-+A:T transitions
accounted for 17, G:C-*T:A transversions for 4, and
G:C-*C:G transversions for 1 mutation (59, 14, and 4% of
the point mutations, respectively). Four of the point muta-
tions at T:A base pairs were T:A-*G:C transversions and
three were T:A-*C:G transitions. The deletions consisted of
three single base pair losses (tumours no. 22, 71, and 418),
one 8 base pair loss (tumour no. 135), and two identical 17
base pair losses (tumours no. 20 and 193, involving codons
174-180).
Neither of the two tumours with stop codon creating
mutations (Table II, no. 78 at codon 204 and no. 434 at
codon 271) contained cells with nuclear p53 protein
accumulation, whereas the only tumour with a sense muta-
tion (Table II, tumour no. 34, codon 128) surprisingly had
p53 protein immunopositive cells.
p53 immunostaining
Immunohistochemistry demonstrated that 35 of 162 primary
carcinomas (22%) and four of 15 metastases (27%) con-
tained cells with nuclear p53 protein accumulation (Table 1).
The p53 protein immunopositive tumours exhibited diffuse or
granular nuclear staining. Representative positive stainings
are shown in Figure 2a-c. No immunoreactivity was seen in
the normal breast tissue surrounding the tumours, but in a
number of cases PAb 240 gave nonspecific binding in connec-
tive tissue. These samples were scored as negative.
Twenty-two tumours were analysed with PAbl801 on
frozen as well as on paraffin embedded tissue. Ten of these
samples were scored as positive and nine as negative on both
frozen and paraffin embedded tissue, whereas three samples
gave positive staining only on paraffin embedded tissue.
The association between TP53 mutation and p53 protein
accumulation was highly significant. Among the 177 tumours
that were analysed for both kind of alterations, nuclear p53
protein accumulation was detected in 32 of 39 mutated and
seven of 138 unmutated samples (P<0.00001). In total 42 of
163 primary tumours (26%) and five of 16 metastases (31%)
had some kind of TP53 alteration.
Relationship to clinical and histopathologicalparameters
Table III gives the relationships between TP53 alterations in
primary tumour and several clinical and histopathological
parameters, including ERBB2 gene amplification. TP53 alter-
ations were significantly more often found in ductal tumours,
tumours with T-status larger than 1, node positive tumours,
oestrogen receptor negative tumours, progesterone receptor
negative tumours, tumours with ERBB2 gene amplification,
and invasive ductal carcinomas.
Univariate survival.analyses
Univariate analyses (Mantel Cox tests) demonstrated
significantly shorter overall and disease-free survival for
patients who had primary tumours with TP53 alterations
(Table IV). TP53 mutation was a somewhat weaker, but
Table III TP53 alterations in relation to clinical and histopathological parameters
TP53 mutation and/or
TP53 mutation p53 protein accumulation p53 protein accumulation
Altered/ Signif. Alteredl Signif. Altered/ Signif.
total level total level total level
Histol. type
Ductal 31/127 (24%) 32/127 (25%) 38/127 (30%)
Others 4/36 (11%) NS 3/35 ( 9%) P=0.060 4/36 (11%) P=0.039
T-status
T= 1 9/76 (12%) 12/76 (16%) 13/76 (17%)
T> 1 26/87 (30%) P = 0.009 23/86 (27%) NS 29/87 (33%) P = 0.0290
Node status
negative 17/100 (17%) 16/99 (16%) 19/100 (19%)
positive 18/59 (31%) P = 0.074 19/59 (32%) P = 0.032 23/59 (39%) P = 0.010
Oestr. rec.
positive 13/109 (12%) 14/109 (13%) 16/109 (15%)
negative 22/54 (41%) P= 0.0001 21/53 (40%) P= 0.0002 26/54 (48%) P= 0.00001
Prog. rec.
positive 12/89 (13%) 13/89 (15%) 14/89 (16%)
negative 23/74 (31%) P = 0.011 22/73 (30%) P = 0.028 28/74 (38%) P = 0.002
ERBB2
amplif. 10/23 (43%) 11/23 (48%) 11/23 (48%)
nonamplif. 19/98 (19%) P = 0.030 16/97 (16%) P = 0.003 21/98 (21%) P = 0.020544 T.I. ANDERSEN et al.
Figure 2 Tumour no. 106. The majority of tumour cells show strong nuclear staining with the monoclonal p53 antibodies a, PAb
421, b, PAb 1801, and c, PAb 240 (x 580).
significant predictor of both overall and disease-free survival, towards reduced overall and
and so was nuclear p53 protein accumulation. Node status TP53 alterations (Figure 3a
represented the most powerful prognostic factor in these
analyses. The node positive patients (n = 59) showed a trend
towards reduced overall survival and had borderline Multivariate survival analyses
significantly reduced disease-free survival if their primary The multivariate analyses s
tumours harboured TP53 alterations, whereas the node alterations as significant vari
negative patients (n= 100) showed non-significant trends vival, whereas node status,
disease-free survival if they had
and b).
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Figure 3 a, Overall survival curves calculated with the life table method by node status and TP53 alterations. A: node neg., TP53
neg. B: node neg., TP53 pos. C: node pos., TP53 neg. D: node pos., TP53 pos. Results of pairwise comparisons of the curves based
on the Mantel cox test, A vs B, P = 0.130; C vs D, P = 0.100. b, Disease free survival curves calculated with the life table method
by node status and TP53 alterations. A: node neg., TP53 neg. B: node neg., TPS3 pos. C: node pos., TP53 neg. D: node pos.,
TP53 pos. Results of pairwise comparisons of the curves based on the Mantel cox test, A vs B, P = 0.170; C vs D, P = 0.050.
were selected as significant variables for predicting disease-
free survival (Table Va and b). When substituting TP53
mutation or nuclear p53 protein accumulation for TP53
alterations in the models, these factors were weaker, but still
statistically significant independent prognostic parameters for
predicting disease-free survival (P = 0.023 and P = 0.036,
respectively). In the overall survival analysis TP53 mutations
were of borderline significance (P = 0.051), whereas p53 pro-
tein accumulation not turned out to be of independent prog-
nostic relevance (P = 0.200).
Discussion
The present work demonstrates TP53 mutations in exons 5
through 8 in 21% of the primary breast carcinomas. The
frequency has previously been reported to be 17-46%
(Kovach et al., 1991; Osborne et al., 1991; Runnenbaum et
al., 1991; Coles et al., 1992; Mazars et al., 1992; Thorlacius et
Table IV Univariate analyses of overall and disease-free survival
Factor Overall survival Disease-free survival
Node status P<0.0001 P<0.0001
TP53 alteration P = 0.0005 P = 0.0002
TP53 mutation P = 0.002 P = 0.001
p53 overexpression P = 0.013 P = 0.002
ERBB2 gene amplification P = 0.008 P = 0.0001
T-status P = 0.046 P = 0.0003
Oestrogen rec. status P = 0.046 P = 0.055
Progesterone rec. status P = 0.049 P=0.027
Table Va Independent prognostic parameters selected by multi-
variate overall survival analysis
Variable P-value Relative hazard
Node status <0.0001 7.3592
TP53 alteration 0.0163 2.9476
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Table Vb Independent prognostic parameters selected by multi-
variate disease-free survival analysis
Variable P-value Relative hazard
Node status <0.0001 6.3561
TP53 alteration 0.0099 2.3128
T-status > 1 0.0227 1.4516
al., 1993). The varying frequencies might be due to
differences in the proportion of early stage patients in the
populations studied. Furthermore, it might reflect that
different regions of the gene have been screened for muta-
tions. In the present work mutations were observed more
frequently in exon 7 (codons 237-253) than in exons 5, 6 and
8 (mutations/base pair screened). This observation is partic-
ularly interesting considering the fact that parts of exon 7 are
extremely well conserved throughout the evolution. The 17
amino acid long stretch encoded by codons 237-253 has
been demonstrated to be identical in rainbow trout, xenopus,
chicken, rat, mouse, monkey, and human (Soussi et al.,
1990).
Six of the mutations detected by CDGE and DGGE were
not confirmed by the sequence analysis. The fact that four of
these tumours had nuclear accumulation of p53 protein
makes it reasonable to believe that the discrepancy is caused
by a lower sensitivity of the sequence analysis than that of
the CDGE. It should be noted that the mutant bands were
faint in three of the six samples, making the identification of
the mutations relyant on the presence of heteroduplexes. The
heteroduplexes that easily are recognised in melting gels
enable detection of mutations when present in 5% or more of
the cell population (Hovig et al., 1992).
In the present work 76% of the point mutations (22/29)
were found at G:C base pairs even though the overall G:C
content in the TP53 gene not is higher than 56% (Coles et
al., 1992). This excess is in accordance with what has been
reported by others (Hollstein et al., 1991; Coles et al., 1992;
de Fromentel & Soussi, 1992). The nucleoside guanosine has
been reported to be a preferential target for most chemical
carcinogens (Kriek et al., 1984). CpG nucleotides are
preferentially thought to be involved in spontaneous muta-
tions (de Fromentel & Soussi, 1992). In the present work
codons 175, 181, 248, 273, and 282 (CGN) that encode
arginine accounted for 12 of the 22 mutations in G:C base
pairs (55%).
The majority of the point mutations were G:C-*A:T tran-
sitions (59%). This frequency is somewhat above the 40%
reported in breast carcinomas by Hollstein et al. (1991), who
further reported the frequency in colon carcinomas and brain
tumours to be 79 and 75%, respectively. G:C-*T:A trans-
versions account for 14% of the point mutations in our
breast carcinomas. It should be noted that such transversions
never have been found in colon carcinomas, but that they
occur at a high frequency in non small cell lung cancer
(57%), liver cancer (74%), and oesophageal cancer (24%),
which are associated with specific mutagenic factors (Holl-
stein et al., 1991). The G:C-*T:A transversions observed in
sporadic breast carcinomas might indicate that external or
internal produced carcinogens take part in the development
of these tumours.
The identification of nuclear accumulation of p53 protein
in 22% of the primary breast carcinomas in the present study
is significantly less than the 57% reported by Thompson et
al. (1990) at the mRNA level, the 54% reported by Bartek et
al., (1990a) using PAb 1801, 240, and 421, and the 45%
reported by Cattoretti et al. (1988) using PAb 1801. On the
other end of the scale positive p53 protein immunostainings
have been reported in 22 and 24% of primary breast car-
cinomas (Crawford et al., 1984; Davidoff et al., 1991b; Thor
et al., 1992). The varying frequencies can be explained by
differences in the proportion of early stage tumours, by
varying quality of the antibodies used, by systematical
differences in interpretation, and by the observation that
frozen samples that have been stored over several years show
a lower frequency of positive reactions (Bartek et al., 1990a).
In accordance with Cattoretti et al. (1988), but in contrast to
Davidoff et al. (199la,b) we interpreted cases with only few
nuclei immunoreactive for p53 protein as immunostaining
positive. Several tumours with positive nuclear staining in
rare cells were demonstrated to contain mutations in the
present study, supporting the interpretation that these
tumours did contain accumulated p53 protein.
In agreement with Cattoretti et al. (1988) and Bartek et al.
(1990b) we found a discrepancy between the immunoreac-
tivity of the different p53 protein monoclonal antibodies.
This could be explained by varying affinity of the antibodies
and by differences in the availability of the epitopes when the
different mutant p53 proteins complex with other proteins
(Yewdell et al., 1986).
The strong association between presence of TP53 muta-
tions and presence of nuclear p53 protein accumulation
(P<0.00001) is in agreement with previous reports (Bartek
et al., 1990b; Davidoff et al., 1991b), and fits the observation
that mutant p53 protein has a half-life exceeding that of
wild-type protein (Nigro et al., 1989). It furthermore
indicates that nuclear p53 protein accumulation in most cases
is due to mutations within the gene.
Mutations were not detected in 7 of the 39 tumours that
were p53 protein immunopositive. These tumours might con-
tain mutations outside the screened regions of the gene, or
they might contain insufficient amounts of mutant cells. Fur-
thermore, some of the tumours might have alternative
mechanisms of TP53 inactivation, such as MDM2 gene
amplification (Momand et al., 1992; Oliner et al., 1992) or
alterations in TP53 regulatory sequences. Recently, two
affected individuals in a cancer prone family were reported to
have high levels of p53 protein constitutively expressed in
their normal epithelial, endothelial, and stromal cells (Barnes
et al., 1992). TP53 was not mutated in these patients, sugges-
ting that mutation in another gene was causing both the high
level of p53 protein and the increased risk ofneoplasia in this
family.
The fact that 7 of 39 samples with mutations were im-
munostaining negative can be explained by presence of sense-
and stop codon mutations (shown for tumours no. 78 and
434, Tables I and II), by frameshift mutations that give lead
to an abnormal aminoacid sequence or to stop codons down
the line, and by the possibility that not all amino acid
substitutions lead to stabile complex formation resulting in
increased half-life. Furthermore, insufficient quality of the
frozen tissue subjected to analysis might lead to false negative
results.
The present work demonstrates that TP53 alterations are
associated with several clinical and histopathological
parameters previously demonstrated to be of prognostic
relevance (Table III). The observation that TP53 alterations
were detected more frequently in oestrogen and progesterone
receptor negative tumours confirms previous findings
(Thompson et al., 1990; Iwaya et al., 1991; Ostrowsky et al.,
1991; Varley et al., 1991; Isola et al., 1992; Thor et al., 1992),
and might reflect lack of differentiation of the breast car-
cinoma cells.
Recently, wild-type p53 has been postulated to be impor-
tant in holding up the cell to repair DNA damage (Levine et
al., 1991; Kuerbitz et al., 1992; Lane, 1992; Vogelstein &
Kinzler, 1992). Tumour cells in which TP53 is inactivated do
not switch off replication in order to allow extra time for
repair. This might explain the observation that primary
tumours with TP53 alterations frequently also contain
ERBB2 gene amplification (Table III) (Horak et al., 1991;
Mazars et al., 1992).
Our data demonstrate that TP53 alterations in primary
breast carcinomas may represent an independent prognostic
parameter for predicting disease-free and overall survival, but
any conclusions based on the multivariate survival analyses
should be drawn with caution. The prognostic relevance was
most pronounced when the data on mutations and protein
accumulation were combined. This probably reflects that
neither mutational analysis nor immunohistochemistry aloneTP53 ALTERATIONS IN BREAST CARCINOMA 547
identifies all TP53 tumour suppressor inactivated tumours.
Node status is the most important established prognostic
factor permitting identification of breast cancer patients at
risk of relapse. Nevertheless, 20-30% of the node negative
patients do relapse (McGuire, 1989). Use of tumour markers
to predict unfavourable prognosis independent of node status
could permit the identification of a subset of node negative
breast carcinoma patients that would benefit from adjuvant
treatment. During the last decade several molecular and cel-
lular markers have been proposed as possible prognostic
indicators (McGuire et al., 1992). In the present material the
node negative patients with TP53 alterations showed trends
towards shortened, although not statistically significant
reduced survival (Figure 3a and b). Further studies will be
required to fully evaluate a possible relevance of TP53 altera-
tions in node negative breast carcinoma.
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